These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24041123)

  • 21. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
    Hadcock JR; Griffith DA; Iredale PA; Carpino PA; Dow RL; Black SC; O'Connor R; Gautreau D; Lizano JS; Ward K; Hargrove DM; Kelly-Sullivan D; Scott DO
    Biochem Biophys Res Commun; 2010 Apr; 394(2):366-71. PubMed ID: 20211605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
    Jacobson LH; Commerford SR; Gerber SP; Chen YA; Dardik B; Chaperon F; Schwartzkopf C; Nguyen-Tran V; Hollenbeck T; McNamara P; He X; Liu H; Seidel HM; Jaton AL; Gromada J; Teixeira S
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):565-81. PubMed ID: 21947251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.
    Liu Q; Bhat M; Bowen WD; Cheng J
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1062-70. PubMed ID: 19752241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
    Son MH; Kim HD; Chae YN; Kim MK; Shin CY; Ahn GJ; Choi SH; Yang EK; Park KJ; Chae HW; Moon HS; Kim SH; Shin YG; Yoon SH
    Int J Obes (Lond); 2010 Mar; 34(3):547-56. PubMed ID: 20029379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant. A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists.
    Chu CM; Hung MS; Hsieh MT; Kuo CW; Suja TD; Song JS; Chiu HH; Chao YS; Shia KS
    Org Biomol Chem; 2008 Sep; 6(18):3399-407. PubMed ID: 18802648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Chronic Alcohol Exposure on the Modulation of Ischemia-Induced Glutamate Release via Cannabinoid Receptors in the Dorsal Hippocampus.
    Zheng L; Wu X; Dong X; Ding X; Song C
    Alcohol Clin Exp Res; 2015 Oct; 39(10):1908-16. PubMed ID: 26343919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.
    Horswill JG; Bali U; Shaaban S; Keily JF; Jeevaratnam P; Babbs AJ; Reynet C; Wong Kai In P
    Br J Pharmacol; 2007 Nov; 152(5):805-14. PubMed ID: 17592509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuation of Cocaine-Induced Conditioned Place Preference and Motor Activity via Cannabinoid CB2 Receptor Agonism and CB1 Receptor Antagonism in Rats.
    Delis F; Polissidis A; Poulia N; Justinova Z; Nomikos GG; Goldberg SR; Antoniou K
    Int J Neuropsychopharmacol; 2017 Mar; 20(3):269-278. PubMed ID: 27994006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of a non-CB1/CB2 cannabinoid receptor in the aqueous humor outflow-enhancing effects of abnormal-cannabidiol.
    Qiao Z; Kumar A; Kumar P; Song ZH
    Exp Eye Res; 2012 Jul; 100():59-64. PubMed ID: 22580290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational investigation on the binding modes of Rimonabant analogs with CB1 and CB2.
    Liu C; Yuan C; Wu P; Zhu C; Fang H; Wang L; Fu W
    Chem Biol Drug Des; 2018 Sep; 92(3):1699-1707. PubMed ID: 29797785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opposite effects of cannabinoid CB
    Li L; Dong X; Tu C; Li X; Peng Z; Zhou Y; Zhang D; Jiang J; Burke A; Zhao Z; Jin L; Jiang Y
    Br J Pharmacol; 2019 Apr; 176(7):890-905. PubMed ID: 30707759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
    Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
    Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in CB1 cannabinoid receptor antagonists.
    Lange JH; Kruse CG
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):498-506. PubMed ID: 15338959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remote Ischemia Preconditioning Attenuates Blood-Spinal Cord Barrier Breakdown in Rats Undergoing Spinal Cord Ischemia Reperfusion Injury: Associated with Activation and Upregulation of CB1 and CB2 Receptors.
    Jing N; Fang B; Wang ZL; Ma H
    Cell Physiol Biochem; 2017; 43(6):2516-2524. PubMed ID: 29130941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The SAR development of substituted purine derivatives as selective CB2 agonists for the treatment of chronic pain.
    Guidetti R; Astles PC; Sanderson AJ; Hollinshead SP; Johnson MP; Chambers MG
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5572-5575. PubMed ID: 25466177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats.
    Adamczyk P; Miszkiel J; McCreary AC; Filip M; Papp M; Przegaliński E
    Brain Res; 2012 Mar; 1444():45-54. PubMed ID: 22325096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
    Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
    Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
    Klumpers LE; Fridberg M; de Kam ML; Little PB; Jensen NO; Kleinloog HD; Elling CE; van Gerven JM
    Br J Clin Pharmacol; 2013 Dec; 76(6):846-57. PubMed ID: 23601084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
    Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
    Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cannabinoid CB
    Weresa J; Pędzińska-Betiuk A; Kossakowski R; Malinowska B
    Pharmacol Rep; 2019 Feb; 71(1):82-89. PubMed ID: 30500553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.